ĀÜĄņĀŅĀ×

Luis Sanchez-Perez has over 10 years of work experience in the field of preclinical translation. Luis is currently the Director of Preclinical Translation at Tune Therapeutics, a position they have held since 2020. Prior to this, they were the Associate Director of Preclinical Translation at Tune Therapeutics. From 2008 to 2020, they were an Assistant Professor at Duke University, where they were responsible for elucidating the mechanisms of ā€œarmoredā€ CAR mediated rejection of heterogeneous brain tumors and designing pre-clinical mouse studies focused on novel immuno-therapeutic approaches against experimental brain tumors. From 2006 to 2008, they were a Research Scientist and Senior Research Associate at the National Cancer Institute, where they evaluated the role of Temozolomide mediated host conditioning on T-cell based immunotherapy against brain tumors and elucidated the mechanisms associated with the induction of supraphysiological levels of antigen-specific antibodies and TMZ-induced lymphopenia.

Luis Sanchez-Perez earned their Doctorate in Immunology from the Mayo Clinic School of Medicine between 2000 and 2006. Prior to that, they obtained a Bachelor of Science in Industrial Biotechnology from the University of Puerto Rico-Mayaguez between 1995 and 2000.